CDK 4/6 Inhibitors: New Choices for HR-Positive, HER2-Negative Metastatic Breast Cancer
This activity includes:
- CME-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck with Facilitator's Guide (a non-certified educational resource)
The goal of this activity is to provide strategies for fellows to incorporate the use of CDK 4/6 inhibitors with a shared decision-making approach into the optimal care of patients with human epidermal growth factor receptor 2–negative metastatic breast cancer.
Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative are the most common subtype of breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies.
Endocrine therapy is the cornerstone of treatment for advanced HR-positive breast cancer. However, not all advanced HR-positive breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. Therefore, improving the efficacy of endocrine therapy in both the adjuvant and metastatic settings would benefit many patients. Significant advances in this area include the development of agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. The CDK 4/6 inhibitor palbociclib when combined with letrozole is first-line therapy for postmenopausal women with HR-positive, HER2-negative MBC. In 2015, the CDK 4/6 inhibitor abemaciclib was granted Breakthrough Therapy designation by the US Food and Drug Administration for use in patients with refractory HR-positive advanced breast cancer.
Providing education that targets the knowledge deficits would benefit most clinicians involved in the management of breast cancer. However, it may be especially crucial for oncology fellows because their role in the treatment of patients with breast cancer and other malignancies will become increasingly prominent. Factors contributing to this include the aging workforce, the observation that the number of oncologists has remained constant despite increased demand, and other trends that raise concerns about a future shortage of medical oncologists.
This activity will provide oncology fellows with the appropriate use of new therapies, such as the CDK 4/6 inhibitors, through a shared decision-making approach for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies.
- Activity Overview
- Overview of HR-Positive Breast Cancer
- The Power of CDK 4/6 Inhibition in HR-Positive Advanced or Metastatic Breast Cancer
- Communication Strategies to Engage Patients in Shared Decision Making
- Practical Application Cases That Feature Treatment Selection and Shared Decision Making
- Activity Conclusion and Q&A
This activity is intended for oncology fellows and other healthcare professionals who treat or manage HR+ metastatic breast cancer.
At the conclusion of this activity, participants should be better able to:
- Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors and why these agents may benefit some patients with advanced or metastatic breast cancer
- Summarize the efficacy and safety profiles of cyclin-dependent kinase 4/6 inhibitors in the treatment of hormone receptor–positive advanced or metastatic breast cancer
- Use a shared decision-making approach with patients who have advanced or metastatic breast cancer to engage them in their care
Sara Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
|Maura N. Dickler, MD|
Interim Chief, Breast Medicine Service
Section Head, Endocrine Therapy, Clinical Research Program
Memorial Sloan Kettering Cancer Center
|Virginia Kaklamani, MD, DSc|
Breast Leader, Professor of Medicine
University of Texas Science Center San Antonio – CTRC
San Antonio, TX
|Ian E. Krop, MD, PhD|
Chief of Breast Medical Oncology
Director of Breast Clinical Research
Associate Professor of Medicine, Harvard Medical School
Ingrid A. Mayer, MD, MSCI
|Ruth M. O’Regan, MD|
Professor of Medicine
Chief, Hemotology/Oncology Division
University of Wisconsin
Carbone Cancer Center
|Joyce O’Shaughnessy, MD|
Baylor-Sammons Cancer Center
|Priya Rastogi, MD|
Sr. Associate Medical Director, NSABP Medical Affairs
Associate Professor of Medicine
UPMC Cancer Institute
|Antoinette Tan, MD, MHSc|
Chief of Breast Medical Oncology
Co-Director of Phase I Program
Levine Cancer Institute
Carolinas HealthCare System
Clinical Professor, Department of Medicine
University of North Carolina
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Sara Tolaney, MD, MPH||Sara Tolaney, MD, MPH, has no real or apparent conflicts of interest to report.|
Adam M. Brufsky, MD, PhD, FACP
Adam M. Brufsky, MD, PhD, FACP, reported a financial interest/relationship or affiliation in the form of: Consultant, Eli Lilly and Company; Research/Grants, Eli Lilly and Company.
|Maura N. Dickler, MD||Maura N. Dickler, MD, reported a financial interest/relationship or affiliation in the form of Research grant through Memorial Sloan Kettering Cancer Center, Genentech/Roche, Novartis Pharmaceuticals Corporation, Eli Lilly and Company; Consultant, Genentech/Roche, Novartis Pharmaceuticals Corporation, Pfizer, Inc., and AstraZeneca Pharmaceuticals.|
|Virginia G. Kaklamani, MD, DSc||Virginia G. Kaklamani, MD, DSc, reported a financial interest/relationship or affiliation in the form of Speakers' bureau, Genentech, Inc., Eisai Inc.; Contracted research, Eisai Inc.|
|Ian E. Krop, MD, PhD||Ian E. Krop, MD, PhD, reported a financial interest/relationship or affiliation in the form of Research grant: Genentech/Roche|
|Ingrid A. Mayer, MD||Ingrid A. Mayer, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, Genentech, Inc; Novartis Pharmaceuticals Corporation.|
|Ruth M. O’Regan, MD||Ruth M. O’Regan, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, Biotheranostics, Astellas; Contracted research: Novartis Pharmaceuticals, Pfizer.|
|Joyce A. O'Shaughnessy, MD||Joyce A. O'Shaughnessy, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Genentech, Inc; Lilly USA; Novartis Pharmaceuticals Corporation; Pfizer, Inc; Zymeworks.|
|Priya Rastogi, MD||Priya Rastogi, MD, has no real or apparent conflicts of interest to report.|
|Antoinette Tan, MD, MHSc||Antoinette Tan, MD, MHSc, reported a financial interest/relationship or affiliation in the form of Contracted research: Merck and Pfizer.|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; and Jocelyn Timko, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is provided by
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance